Our discovery starts with patient data powered by AI, using the unique RNA signature of the patient to build an in-silico network using systems biology and our proprietary foundation model of human health. No data? We developed a home collection kit for RNAseq, which we deploy globally using our rareSHIFT discovery program.

We rapidly identify therapeutic mechanisms regardless of root cause of the disease and use our proprietary database to specify molecules to restore health. If needed, we build animal models in a matter of weeks to ask clinically relevant questions about efficacy and safety. Patients can’t wait for decades of basic research.

We derisk discovered therapeutic mechanisms in real patients using the off-target effects of existing drugs, letting us clinically derisk the therapeutic impact of new biology incredibly quickly and efficiently. By prototyping, we can more quickly and inexpensively discover what truly works. This helps patients today, while derisking new therapeutics we develop in parallel. We have enabled clinicians to achieve clinical efficacy in 100% of the patients we analyzed.